VEGFA and ovarian carcinoma: The concurrent and maintenance anti‐VEGF bevacizumab was later recommended for the standard first‐line systemic treatment of epithelial ovarian cancer, which improves PFS in patients with higher risk of recurrence (International Federation of Gynecology and Obstetrics FIGO stage IV or suboptimally debulked stage III ovarian cancer—OC).113